Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study
10.5468/ogs.2019.62.5.344
- Author:
Shoou Chern LI
1
;
Youngmi WANG
;
Seong Jin CHOI
;
Yeon Soo JUNG
;
Kyoung Hee HAN
;
In Bai CHUNG
;
San Hui LEE
Author Information
1. Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea. sanaram@yonsei.ac.kr
- Publication Type:Randomized Controlled Trial
- Keywords:
Postoperative nausea and vomiting;
Ramosetron;
Laparoscopy;
Hysterectomy
- MeSH:
Anesthesia, General;
Antiemetics;
Humans;
Hysterectomy;
Incidence;
Laparoscopy;
National Health Programs;
Nausea;
Postoperative Nausea and Vomiting;
Postoperative Period;
Prospective Studies;
Vomiting
- From:Obstetrics & Gynecology Science
2019;62(5):344-351
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The purpose of this study was to evaluate the effectiveness of scheduled ramosetron injections for controlling postoperative nausea and vomiting (PONV) after single-port access total laparoscopic hysterectomy (SPA-TLH). METHODS: Ninety patients who underwent SPA-TLH at the Korean National Health Insurance Service Ilsan Hospital between June 2013 and July 2014 were enrolled in this prospective, randomized, double-blinded, placebo-controlled study. The patients were divided into 2 groups as follows: the ramosetron group (0.3 mg intravenously [IV]; n=45) and the placebo group (normal saline IV; n=45). Both groups received their respective injections 12 and 24 hours post surgery. The incidence and severity of PONV (numerical rating scale, 0–10), and the use of rescue antiemetics post surgery were evaluated. RESULTS: Demographic and perioperative statistically significant differences were not observed between the 2 groups. The incidence of PONV in the ramosetron and placebo groups was 46.7% and 51.1%, respectively (P=0.51). We found significant differences in the severity of PONV between the 24- to 48-hour postoperative periods in both groups (ramosetron group, P=0.04 and placebo group, P=0.03). The use of rescue antiemetics was significantly lower in the ramosetron group than in the placebo group (P=0.02). CONCLUSION: After general anesthesia, scheduled injections of ramosetron 12 and 24 hours after SPA-TLH reduced the severity of PONV and the use of rescue antiemetics. Administration of ramosetron can be considered not only immediately after SPA-TLH but also during the first 24-hour recovery period. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT 02011659
